Loading…
This event has ended. Visit the official site or create your own event on Sched.
View analytic
Sunday, April 29 • 11:20am - 12:00pm
Managing IBD with Targeted Pathophysiologic Strategies

Sign up or log in to save this to your schedule and see who's attending!

Feedback form is now closed.
Advances in the understanding of inflammatory cascades and the role of cytokines and cell adhesion molecules in IBD pathogenesis has led to a therapeutic shi from general immunosuppressive therapy toward a more pathway-based approach. The identification of specific immunomodulatory molecules that possess defined pathogenic roles, such as pro-inflammatory cytokines, led to the advent of several anti-TNF monoclonal antibodies that have become the mainstay of IBD treatment.

However, the utilization of these agents is o en not maximized. Even among patients appropriately treated with anti-TNF agents, less than half achieve clinical remission and mucosal healing, suggesting the involvement of other immunologic pathways.

Thus, this session will focus on maximizing current biologic therapies, overcoming treatment challenges, the underlying mechanisms of IBD as treatment targets, and exploring new and emerging therapies that may complement the current treatment armamentarium. 

Speakers
avatar for Stephen B. Hanauer, MD

Stephen B. Hanauer, MD

Clifford Joseph Barboka Professor of Medicine, Northwestern University Feinberg School of Medicine; Medical Director, Digestive Health Center
Stephen B. Hanauer, MD, FACG is an internationally recognized expert on the treatment of inflammatory bowel disease (IBD), former chair of the FDA Gastrointestinal Drugs Advisory Committee and advisor on the development of multiple leading IBD drugs.   Dr. Hanauer is a board c... Read More →


Sunday April 29, 2018 11:20am - 12:00pm
TBA